How to fully prepare your team for an effective competitor response strategy?[1] [2]
[1] Do you understand the threats posed by both your innovative and biosimilar competitors looking to disrupt your established leadership?
[2] How can you optimise your competitor response strategy to maintain leadership in your disease area?
- What are your competitors’ strategic approaches to launches?
- What are the key threats posed by them that will be most impactful to you?
- How aggressively will the biosimilar competitors approach the tenders?
- What are the best approaches to mitigate these competitive threats? Any gaps?
- How do you optimise your portfolio strategy to grow your revenues across the franchise?
- How do ensure your cross-functional and regional teams are aligned with the same response strategy?
What we did
Our cross-portfolio support and holistic view of competitive threats enabled us to offer integrated thought partnership. We devised a set of meaningful strategic imperatives for our client’s competitive response blueprint, enabling them to continue building their leadership in the evolving competitive landscape.
Building on this success, we are now supporting them on an expanded scope of competitor monitoring, and their biosimilar response strategy.
How we did it
Conducted primary interviews with our network of KOLs and industry experts and combined this with our deep understanding of the space to distill the go-to market strategies of key and upcoming competitors.
Designed and facilitated cross-functional competitor simulations to produce a prioritised set of actionable outcomes, with direct commercial applications, to prepare for upcoming competitor entries